Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Factors that modulates inflammatory response
- Knockdown of the α7nAChR
- Expression of a7nAChR by primary RA FLS
- Expression of a7nAChR in several cell types
- VNS attenuates acute inflammation
- Cholinergic anti-inflammatory pathway
- Aggravation of collagen-induced arthritis
- Anti-collagen II antibodies in plasma
- Antigen-specific stimulation of splenocytes
- Reduced arthritis after oral nicotine treatment
- Treatments with a7nAChR activator or agonist (1)
- Treatments with a7nAChR activator or agonist (2)
- TNF level after treatment with a7nAChR regulators
- The cholinergic anti-inflammatory pathway and CIA
- Cholinergic pathway and chronic inflammation
- Heart rate variability
- Autonomic balance in individuals at risk of RA
- RHR ≥ 70 bpm in those at risk of developing RA
- RHR is higher in individuals at risk of RA
- Proposed novel strategy for RA treatment
- VNS reduces signs and symptoms of CIA
- Inflammatory reflex activation and cytokine
- The effects of VNS on cytokine production
- Inflammatory reflex activation reduces TNF level
- Inflammatory reflex activation and IL-6 & IL-1β
- Open label trial in RA with withdrawal period
- Mean change in DAS28-CRP through day 84
- Chronic VNS reduces LPS-induced TNF release
- Endurance of the therapeutic effect of VNS
- Sustained decrease in HAQ-DI
- Independent confirmation of our results in RA&CD
- Conclusions
- Acknowledgements
Topics Covered
- Role of the cholinergic anti-inflammatory pathway or inflammatory reflex in chronic inflammation
- How its role was discovered in a prototypic immune-mediated inflammatory disease (rheumatoid arthritis)
- Bioelectronic vagus nerve stimulation effect on cytokine production and reduction of disease activity in chronic inflammatory disease
- Opportunity to treat a wide variety of conditions using bioelectronics
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Tak, P.P. (2019, September 26). Bioelectronic medicine: immunomodulation by vagus nerve stimulation [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 20, 2024, from https://doi.org/10.69645/GYZM8921.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Tak has previously been a consultant to SetPoint Medical and a Member of the Board of Directors of Galvani Bioelectronics.
Bioelectronic medicine: immunomodulation by vagus nerve stimulation
Published on September 26, 2019
27 min
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
I'm Paul Peter Tak,
I'm a Professor of Medicine at the Amsterdam University Medical Center.
What if I told you that you can treat chronic immune mediated
inflammatory disease by electrons rather than by small molecules?
In other words, what if I told you that we can treat patients with
bio-electronic medicine rather than with tablets or injections?
Well, we can, and that's what I'm going to show you,
and I will show you how we got to this discovery in chronic autoimmune disease.
0:36
It starts with the identification of factors that are involved in
the modulation of the response in rheumatoid arthritis in
the key effective cell called the fibroblast-like synoviocytes
and we obtained synovial tissue samples from patients with active rheumatoid arthritis,
so they have an actively inflamed joint with pain and swelling,
and we obtained these samples using arthroscopy.
Then in the lab,
we cultured these fibroblast-like synoviocytes,
we seeded them using a library of more than 2,000
adenoviral shRNAs against 807 transcripts.
Then five days after transduction,
we added TNF to the medium and read out the production of key
cytokines/chemokine involved in the pathogenesis
of rheumatoid arthritis namely Interleukin 8,
and we also looked at the production of degrading enzymes,
matrix metalloproteinases because these are involved in
the destruction of the bone and cartilage in rheumatoid arthritis,
which is a chronic inflammatory disease of the joints.